Tear fluid gelatinase B activity correlates with IL-1α concentration and fluorescein clearance in ocular rosacea

Investigative Ophthalmology and Visual Science

Volumn 40, Issue 11, 1999, Pages 2506-2512

  Afonso, Adolfo A ^b   Sobrin, Lucia ^b   Monroy, Dagoberto C ^b   Selzer, Marie ^b   Lokeshwar, Balakrishna ^b   Pflugfelder, Stephen C ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; INTERLEUKIN 1;

ADULT; AGED; ARTICLE; CLEARANCE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE IRRITATION; FEMALE; FLUORESCENCE; HUMAN; LACRIMAL FLUID; MALE; PRIORITY JOURNAL; ROSACEA; ZYMOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; COLLAGENASES; CONJUNCTIVAL DISEASES; CORNEAL DISEASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCEIN; FLUOROPHOTOMETRY; HUMANS; INTERLEUKIN-8; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; ROSACEA; TEARS;

EID: 0032871943     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Lemp MA. Report of the National Eye Institute/Industry Workshop on clinical trials in dry eyes. CLAO J. 1995;21:222-232.
2. Pflugfelder SC, Tseng SCG, Sanabria O, et al. Evaluation of subjective assessments and objective diagnostic tests for diagnosing tearfilm disorders known to cause ocular irritation. Cornea. 1998;17: 38-56.
3. Afonso A, Monroy D, Tseng SCG, Stern M, Pflugfelder SC. Diagnostic sensitivity and specificity of Schirmer test and fluorescein clearance test for ocular irritation. Ophthalmology. 1999;106:803-810.
4. Jenkins MS, Brown SI, Lempert SL, Weinberg RJ. Ocular rosacea. Am J Ophthalmol. 1979;88:618-622.
5. Wise G. Ocular rosacea. Am J Ophthalmol. 1943;26:591-609.
6. Akpek EK, Merchard A, Pinar V, Foster CS. Ocular rosacea: patient characteristics and follow-up. Ophthalmology. 1997;104:1863-1867.
7. Browning DJ, Proia A. Ocular rosacea. Surv Ophthalmol. 1986;31: 145-158.
8. Driver PJ, Lemp MA. Meibomian gland dysfunction. Surv Ophthalmol. 1996;40:343-367.
9. Netland PA, Sugrue SP, Albert DA, Shore JW. Histopathologic features of the floppy eyelid syndrome. Ophthalmology. 1994;101: 174-181.
10. Gonnering RS, Sonneland PR. Meibomian gland dysfunction in floppy eyelid syndrome. Ophthalmol Plastic Reconstr Surg. 1987; 3:99-103.
11. Barton K, Monroy D, Nava A, Pflugfelder SC. Inflammatory cytokines in tears of patients with ocular rosacea. Ophthalmology. 1997;104:1868-1874.
12. Woessner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991;5:2145-2154.
13. Suto TS. In vivo transfer of engineered macrophages into the glomerulus: endogenous TGF-beta-mediated defense against macrophage-induced glomerular cell activation. J Immunol. 1997;159: 2476-2483.
14. Esteve PO. In vitro expression of MMP-2 and MMP-9 in glioma cells following exposure to inflammatory mediators. Biochim Biophys Acta. 1998;1403:85-96.
15. Samples JR. Regulation of the levels of human trabecular matrix metalloproteinases and inhibitor by interleukin-1 and dexamethasone. Invest Ophthalmol Vis Sci. 1993;34:3386-3395.
16. Vu TH. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell. 1998;93:411-422.
17. Norn M. Meibomian gland orifices and Marx's line: studied by triple vital staining. Acta Ophthalmol. Scand. 1985;63:698-700.
18. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell. 1997;91:439-442.
19. Matsubara M, Zieske JD, Fini ME. Mechanism of basement membrane dissolution preceding corneal ulceration. Invest Ophthalmol Vis Sci. 1991;32:3221-3237.
20. Fini ME, Parks WC, Rinehart WB, et al. Role of matrix metalloproteinases in failure to re-epithelialize after comeal injury. Am J Pathol. 1996;149:1287-1301.
21. Fini ME, Girard MT, Matsubara M. Collagenolytic/gelatinolytic enzymes in corneal wound healing. Acta Ophthalmol. 1992;70(suppl 202):26-33.
22. Ye HQ, Azar DT. Expression of gelatinases A and B and TIMPs 1 and 2 during corneal wound healing. Invest Ophthalmol Vis Sci. 1998;39:913-921.
23. Jones DT, Monroy D, Pflugfelder SC. A novel method of tear collection: comparison of glass capillary tubes with porous polyester rods. Cornea. 1997;16:450-458.
24. Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK, Pflugfelder SC. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea. 1998;17:584-589.
25. Schafer M, Carter L, Stein C. Interleukin 1β and corticotropin releasing factor inhibit pain by releasing opioids from immune cells in inflamed tissue. Proc Natl Acad Sci. 1994:4219-4223.
26. Jordan A, Baum J. Basic tear flow: does it exist? Ophthalmology. 1980;87:920-930.
27. Heigle TJ, Pflugfelder SC. Aqueous tear production in patients with neurotrophic keratitis. Cornea. 1996;15:135-138.
28. Huang HY, Wen Y, Irwin JC, Kruessel JS, Soong YK, Polan ML. Cytokine-mediated regulation of 92-kilodalton type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-3 messenger ribonucleic acid expression in human endometrial stromal cells. J Clin Endocrinol Metab. 1998;83:1721-1729.
29. O'Boskey FJJ, Panagakos FS. Cytokines stimulate matrix metallo-proteinase production by human pulp cells during long-term culture. J Endodontics. 1998;24:7-10.
30. Samples JR, Alexander JP, Acott TS. Regulation of the levels of human trabecular matrix metalloproteinases and inhibitor of interleukin-1 and dexamethasone. Invest Ophthalmol Vis Sci. 1993;34: 3386-3395.
31. van der Zee E. EGF and IL-1 alpha modulate the release of collagenase, gelatinase and TIMP-1 as well as the release of calcium by rabbit calvarial bone expiants. J Periodontal Res. 1998;33:65-72.
32. Ingman T. Matrix metalloproteinases and their inhibitors in gingival crevicular fluid and saliva of periodontitis patients. J Clin Periodontol. 1996;23:1127-1132.
33. Makela M. Matrix metalloproteinases (MMP-2 and MMP-9) of the oral cavity: cellular origin and relationship to periodontal status. J Dent Res. 1994;73:1397-1406.
34. Nakaya H, Oates TW, Hoang AM, Cochran DL. Effects of interleukin-1β on matrix metetalloproteinase-3 levels in human periodontal ligament cells. J Periodontol. 1997;68:517-523.
35. Van Wart HE, Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci USA. 1990;87:5578-5582.
36. Itoh Y, Nagase H. Preferential inactivation of tissue inhibitor of matrix-metalloproteinase-1 that is bound to precursor matrix metalloproteinase 9 (progelatinase B) by human neutrophil elastase. J Biol Chem. 1995;270:16518-21.
37. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem Hoppe-Seyler. 1997;378:151-160.
38. Virtanen T. Tear fluid plasmin activity of dry eye patients with Sjogren's syndrome. Acta Ophthalmol Scand. 1997;75:137-141.
39. Tan KO, Sack RA, Holden BA, Swarbrick HA. Temporal sequence of changes in tear film composition during sleep. Curr Eye Res. 1993;12:1001-1007.
40. Sakata M. Polymorphonuclear leukocyte cells and elastase in tears. Curr Eye Res. 1997;16:810-819.
41. Thakur A, Willcox MD, Stapleton F. The proinflammatory cytokines and arachidonic acid metabolites in human overnight tears: homeostatic mechanisms. J Clin Immunol. 1998;18:61-70.